Antimicrobial Spectrum of Gatifloxacin in the SENTRY Program

Jones, R.N.; Pfaller, M.A.; Doern, G.V.; Beach, M.
December 1999
Drugs;Dec1999 Supplement 2, Vol. 58 Issue 6, p173
Academic Journal
Reports on the use of quinolones against isolates from respiratory tract, urinary tract, skin and soft tissue and bloodstream infections. Materials and methods; Results and discussion.


Related Articles

  • Gemifloxacin: A broad-spectrum oral quinolone for treatment of respiratory and urinary tract infections. Lomaestro, Ben M. // Formulary;Dec2000, Vol. 35 Issue 12, p961 

    Examines the pharmacokinetic and pharmacodynamic characteristics of gemifloxacin, a potent fluoroquinolone, against several pathogens. Use of gemifloxacin in the treatment of respiratory and urinary tract infections; Drug interactions; Adverse effect profile.

  • Clinical Importance and Epidemiology of Quinolone Resistance. E니 Suk Kim; Hooper, David C. // Infection & Chemotherapy;Dec2014, Vol. 46 Issue 4, p226 

    The quinolone class of antimicrobial agents is one of most widely used classes of antimicrobial agents in outpatient and inpatient treatment. However, quinolone resistance in gram-positive and gram-negative bacteria has emerged and increased globally. This resistance limits the usefulness of...

  • Gatifloxacin-induced prolongation of QTc interval. Shah, V. N.; Karavadara, N. R.; Shah, D. S.; Shah, B. K. // Indian Journal of Pharmacology;Feb2006, Vol. 38 Issue 1, p60 

    The article studies gatifloxacin-induced prolongation of corrected Q-T (QTc) interval in lower respiratory trace infections and urinary tract infections. Drug-induced QTc prolongation is increasingly being recognized as an adverse event associated with fluoronuinolone. The authors conclude that...

  • THE ASSESSMENT OF ANTIBIOTICS THERAPIES IN DIFFERENT GROUPS IN ACUTE CYSTITIS IN TERMS OF PHARMAECONOMICAL ASPECTS. İlbars, Hilal; Özçelikay, Gülbin // Turkish Journal of Pharmaceutical Sciences;2011, Vol. 8 Issue 3, p219 

    The urinary tract infection (UTI) is the second most common community acquired infection following the upper respiratory tract infections. In this study 160 subjects aged between 18-65 years with the diagnosis of acute cysytitis between 2005-2006 were involved and the objective was to determine...

  • Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China. Ying-yuan Zhang; Hai-hui Huang; Zhen-yi Ren; Hong-guang Zheng; Yun-song Yu; Xiao-ju Lü; Zu-ke Xiao; Hui-fen Yang; Qing-yu Xiu; Bao-yuan Chen; Hong-mei Yue; Qing-lin Hao; Jian-an Huang; Hui Ma; Wei Xiao; Dong-yang Guo; Bin Si; Sheng-hua Sun; Wei Zhang; Qi-hao Li // Journal of Infection & Chemotherapy (Springer Science & Business;Oct2009, Vol. 15 Issue 5, p301 

    Abstract  Levofloxacin (LVFX), a fluoroquinolone agent, has a broad spectrum that covers Gram-positive and -negative bacteria and atypical pathogens. It demonstrates good clinical efficacy in the treatment of various infections, including lower respiratory tract infections (LRTIs) and...

  • UTIs: Consider short-course quinolone in older women.  // Geriatrics;Mar97, Vol. 52 Issue 3, p85 

    Presents an abstract of the article `3-day Course of Ofloxacin Versus Cefalexin in the Treatment of Urinary Tract Infections in Postmenopausal Women,' by R. Raz and S. Rozenfeld in `Antimicrobial Agents and Chemotherapy' dated 1996.

  • New help for urinary tract infections. Zamula, Evelyn // FDA Consumer;Jun95, Vol. 29 Issue 5, p15 

    Deals with the prevalence of urinary tract infection (UTI) among women and the development of drugs to treat both uncomplicated UTIs and more serious ones. Food and Drug Administration's approval of a group of drugs called quinolones; Symptoms of infections; Escherichia coli infections; Role of...

  • Once-daily quinolone effective for uncomplicated UTI. Benkhead, Charles // Urology Times;Jan2003, Vol. 31 Issue 1, p4 

    Discusses the efficacy of quinolone for treating uncomplicated urinary tract infection (UTI). Approval of the Food and Drug Agency on the extended-release formulation of the drug; Advantages of treatment; Signs and symptoms of uncomplicated UTI.

  • Gemifloxacino para el tratamiento de infecciones no complicadas de las vías urinarias (cistitis aguda). M. Blondeau, Joseph; S. Tillotson, Glenn // Ginecologia y Obstetricia de Mexico;dic2010, Vol. 77 Issue 12, p573 

    Uncomplicated urinary infections are a significant and growing cause of morbidity amongst young women. Commonly these infections are caused by Escherichia coli or Staphylococcus saprophyticus. Escherichia coli is resistant to several empirical antibiotics: amoxicilin, trimetoprima-sulfametozaxol...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics